CL2018003649A1 - Edición genética mejorada - Google Patents

Edición genética mejorada

Info

Publication number
CL2018003649A1
CL2018003649A1 CL2018003649A CL2018003649A CL2018003649A1 CL 2018003649 A1 CL2018003649 A1 CL 2018003649A1 CL 2018003649 A CL2018003649 A CL 2018003649A CL 2018003649 A CL2018003649 A CL 2018003649A CL 2018003649 A1 CL2018003649 A1 CL 2018003649A1
Authority
CL
Chile
Prior art keywords
genetic editing
enhanced genetic
editing
enhanced
recombinases
Prior art date
Application number
CL2018003649A
Other languages
English (en)
Spanish (es)
Inventor
Adam Brian Robertson
Julia Robertson
Anika Reifschneider
Arne Klungland
Original Assignee
Univ Oslo Hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oslo Hf filed Critical Univ Oslo Hf
Publication of CL2018003649A1 publication Critical patent/CL2018003649A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2018003649A 2016-06-16 2018-12-17 Edición genética mejorada CL2018003649A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662350941P 2016-06-16 2016-06-16

Publications (1)

Publication Number Publication Date
CL2018003649A1 true CL2018003649A1 (es) 2019-07-05

Family

ID=65019181

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003649A CL2018003649A1 (es) 2016-06-16 2018-12-17 Edición genética mejorada

Country Status (7)

Country Link
US (2) US11708588B2 (enExample)
EP (1) EP3472329A1 (enExample)
JP (1) JP2020511931A (enExample)
CN (1) CN109790551A (enExample)
CA (1) CA3028074A1 (enExample)
CL (1) CL2018003649A1 (enExample)
WO (1) WO2018229521A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020284581A1 (en) * 2019-05-29 2021-12-23 Monsanto Technology Llc Directed genome engineering using enhanced targeted editing technologies
CN112979821B (zh) * 2019-12-18 2022-02-08 华东师范大学 一种提高基因编辑效率的融合蛋白及其应用
CN111518220A (zh) * 2020-05-14 2020-08-11 重庆英茂盛业生物科技有限公司 一种融合蛋白及其设计方法
CN111909961B (zh) * 2020-08-21 2022-04-19 华侨大学 一种CRISPR/Cas介导的ATL细胞基因编辑载体及其应用
US20230407339A1 (en) * 2020-11-06 2023-12-21 The University Of Hong Kong Transferable type i-f crispr-cas genome editing system

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7868149B2 (en) 1999-07-20 2011-01-11 Monsanto Technology Llc Plant genome sequence and uses thereof
US6603061B1 (en) 1999-07-29 2003-08-05 Monsanto Company Agrobacterium-mediated plant transformation method
CA2434402A1 (en) 2001-01-10 2002-07-18 Amaxa Gmbh Modular transfection systems
US20090100536A1 (en) 2001-12-04 2009-04-16 Monsanto Company Transgenic plants with enhanced agronomic traits
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
EP3450563A1 (en) * 2011-02-25 2019-03-06 Recombinetics, Inc. Genetically modified animals and methods for making the same
EP2895620B1 (en) * 2012-09-11 2017-08-02 Life Technologies Corporation Nucleic acid amplification
CA2889502A1 (en) * 2012-10-30 2014-05-08 Recombinetics, Inc. Control of sexual maturation in animals
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
US8697359B1 (en) * 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CN105492611A (zh) * 2013-06-17 2016-04-13 布罗德研究所有限公司 用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物
SG10201804973TA (en) 2013-12-12 2018-07-30 Broad Inst Inc Compositions and Methods of Use of Crispr-Cas Systems in Nucleotide Repeat Disorders
CN104946621A (zh) 2014-03-28 2015-09-30 中国科学院上海生命科学研究院 基因敲入组合物及其使用方法和应用
EP3180426B1 (en) * 2014-08-17 2019-12-25 The Broad Institute, Inc. Genome editing using cas9 nickases
WO2016054326A1 (en) 2014-10-01 2016-04-07 The General Hospital Corporation Methods for increasing efficiency of nuclease-induced homology-directed repair
AU2015342749B2 (en) 2014-11-07 2022-01-27 Editas Medicine, Inc. Methods for improving CRISPR/Cas-mediated genome-editing
EP3274453B1 (en) * 2015-03-26 2021-01-27 Editas Medicine, Inc. Crispr/cas-mediated gene conversion
US9988637B2 (en) * 2015-10-26 2018-06-05 National Tsing Hua Univeristy Cas9 plasmid, genome editing system and method of Escherichia coli

Also Published As

Publication number Publication date
JP2020511931A (ja) 2020-04-23
US11708588B2 (en) 2023-07-25
WO2018229521A1 (en) 2018-12-20
CN109790551A (zh) 2019-05-21
WO2018229521A8 (en) 2019-02-28
US20230416788A1 (en) 2023-12-28
US20220010336A1 (en) 2022-01-13
EP3472329A1 (en) 2019-04-24
CA3028074A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
CL2018003649A1 (es) Edición genética mejorada
CY1125385T1 (el) Συστημα πολλαπλων φορεων και χρησεις αυτου
MX2019009361A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
ECSP17074016A (es) Producción de vectores adeno-asociados de gran tamaño
MX382223B (es) Regulacion de expresion genica mediada por nucleasa.
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
BR112019003100A2 (pt) regulação da expressão gênica usando nucleases manipuladas
SA517390590B1 (ar) Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة
MX374529B (es) Suministro, uso y aplicaciones terapeuticas de sistemas y composiciones crispr-cas para edicion del genoma.
CO2017004290A2 (es) Composiciones y métodos para el silenciamiento de la expresión génica del virus de la hepatitis b
CY1123119T1 (el) Αντινοηματικο νουκλεϊκο οξυ
MX2017005958A (es) Composiciones de acido ribonucleico de interferencia (arni) contra el virus de la hepatitis b (hbv) y metodos de uso de estas.
BR112018002600A2 (pt) células para imunoterapia modificadas para direcionamento ao antígeno cd38 e para inativação do gene cd38
BR112017024123A2 (pt) construtos de expressão e métodos de manipulação por engenharia genética de levedura metilotrófica
MX2017008190A (es) Metodos y composiciones para la modificacion genetica dirigida a traves de direccionamiento multiple de una sola etapa.
BR112016023814A2 (pt) mutações visadas
MX368723B (es) Composiciones y metodos para inhibir la expresion del gen alas1.
MX388294B (es) Peptidos y nanoparticulas para suministro intracelular de moleculas editoras de genoma.
PH12016502555A1 (en) Methods of preparing substituted nucleotide analogs
MX2018001055A (es) Promotores para mejorar la expresion en poxvirus.
AU2017250265A1 (en) Methods for creating synthetic chromosomes having gene regulatory systems and uses thereof
AR097486A1 (es) Plantas de cítricos resistentes a huanglongbing de cítricos (ex enverdecimiento) producido por candidatus liberibacter asiaticus (las) y chancro bacteriano producido por xanthomonas axonopodis pv. citri (xac)
MX2017014206A (es) Introgresion de un rendimieno qtl en plantas de cucumis sativus.
MX2017004034A (es) Mutantes de recombinasas.
EA201990568A1 (ru) Регулирование экспрессии генов с использованием сконструированных нуклеаз